Single-Dose GnRH Antagonist for Recurrent Acute Urinary Retention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute urinary retention (AUR) are ineffective in preventing recurrence and often require frequent administrations, leading to patient discomfort and healthcare burden, with α-blockers showing minimal benefit and 5-α-reductase inhibitors having a slow reaction time, while catheterization provides only temporary relief.
Innovation Solution
A single dose of a GnRH antagonist, such as teverelix, is administered to rapidly reduce prostate volume and prevent recurrent AUR by blocking GnRH receptors, thereby reducing testosterone levels and prostate size without causing long-term hypogonadism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If α-blockers are used to treat AUR, then lower urinary tract symptoms are alleviated, but the treatment fails to prevent recurrence of AUR
Solution Approach 1:
The patent changes the pharmacological parameter from α-adrenergic blockade to GnRH receptor antagonism, thereby changing the mechanism of action from smooth muscle relaxation to hormonal suppression of prostate growth, achieving both symptom relief and recurrence prevention
2Reliability
If 5-α-reductase inhibitors are used to reduce prostate volume, then the risk of AUR is reduced, but the reaction time is too slow for acute episodes
Solution Approach 1:
The GnRH antagonist acts preliminarily and rapidly to suppress testosterone production before the acute AUR episode worsens, achieving fast onset of action within days rather than months, thereby preventing recurrence while maintaining adequate prostate volume reduction
Solution Approach 2:
The patent changes the kinetic parameter of the drug action from slow (5-α-reductase inhibitors taking months) to fast (GnRH antagonists acting within days), achieving both rapid symptom relief and effective prostate volume reduction
3Reliability
If repeated catheterizations are performed to manage AUR, then bladder decompression is achieved, but patient quality of life deteriorates and healthcare burden increases
Solution Approach 1:
The GnRH antagonist is administered preliminarily to reduce prostate volume and relieve obstruction before acute retention episodes occur, thereby preventing the need for repeated catheterizations and improving quality of life while maintaining reliable bladder decompression capability
Solution Approach 2:
The patent extracts the need for repeated invasive catheterization procedures by implementing a pharmacological prevention strategy that addresses the root cause (prostate enlargement) rather than just the symptom (urinary retention), thereby eliminating the burden of repeated interventions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The single dose of teverelix effectively reduces prostate volume by at least 10% within four weeks, significantly lowering the risk of recurrent AUR and associated complications, while minimizing side effects by maintaining testosterone levels above 0.5 ng/mL and avoiding long-term low testosterone issues.
Implementation Method 1
GnRH antagonists compete with the endogenous neurohormone GnRH (also known as luteinizing hormone releasing hormone, LHRH) for binding to its receptors in the anterior pituitary gland. By decreasing or blocking GnRH action, GnRH antagonists suppress release from the anterior pituitary gland of follicle stimulating hormone (FSH) and luteinizing hormone (LH).
Data Source
Figure 1A~1D
Figure 2
AI summary
The present invention relates to a composition comprising at least one GnRH antagonist for use in reducing the risk of recurrent acute urinary retention (AUR) in males of least 45 years of age presenting with a first episode of AUR. Said composition can within four week effectively alleviate urethral obstruction caused by an enlarged prostate, and restore normal urine flow without the need for surgery.